Hyperion Investments Pte. Ltd., a Singapore-based shareholder, sold 24,160,000 equity shares of Dr. Agarwal's Health Care on August 12, 2026. The off-market or open market disposal via stock exchanges reduced its total holding in the healthcare company significantly.

The sale brought Hyperion's stake down from 73,193,988 shares, representing 23.09% of the total voting capital, to 49,033,988 shares, or 15.47%. The diluted shareholding similarly contracted from 22.93% to 15.36%.

Transaction Details

The disclosure was filed with the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on August 13, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Hyperion confirmed that it does not belong to the promoter or promoter group of Dr. Agarwal's Health Care. There were no encumbrances, pledges, liens, or non-disposal undertakings on the shares held by Hyperion before or after the transaction.

What the Numbers Show

The sale represents a substantial reduction in institutional exposure, with Hyperion divesting approximately one-third of its previous holding. The company's total equity share capital remained unchanged at 316,983,028 fully paid-up equity shares of ₹1 each, indicating the transaction was a secondary sale between investors rather than a primary issuance or buyback.

Dr. Agarwal's Health Care Limited saw a reduction in its pledged shareholding after Catalyst Trusteeship Limited released encumbrance over a significant portion of its equity shares. The security agent, acting for lenders to Hyperion Investments Pte. Ltd., disclosed the release of 31,698,303 equity shares on August 11, 2026.

The disclosure was made under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The shares were originally pledged as security for a facility agreement dated March 26, 2024, between Hyperion Investments Pte. Ltd. and certain lenders. The facility aggregated up to USD 100,000,000.

Pledge Position Update

Prior to this release, Catalyst Trusteeship held an encumbrance over 73,193,988 equity shares, which constituted 23.09% of the total share capital and 22.93% of the diluted share capital. Following the partial release, the remaining encumbered shares stand at 41,495,685.

The release of encumbrance is treated as a disposal under Regulation 29(2) read with Regulation 29(4) of the Takeover Code. No acquisition or sale of shares carrying voting rights occurred during this transaction.

What the Numbers Show

The data reveals a significant de-leveraging event within the promoter group's collateral structure. By releasing nearly 43% of the previously pledged block (31.69 million out of 73.19 million shares), the borrower has substantially reduced the security interest held by lenders. While 13.09% of the voting capital remains encumbered, the reduction from a 23.09% pledge level indicates improved liquidity or debt repayment capacity relative to the initial facility terms established in March 2024.